Answers are grounded in this paper and cite their sources.
The Janus kinase 2 (JAK2) is a drug target in particular because a missense mutation in this gene (V617F) has been identified in various human diseases. We report here the first kinetic study of the human full-length wild type and V617F JAK2 proteins and of their isolated kinase domain. The kinetic parameters of both full-length proteins are similar revealing that the mutation does not affect JAK2 catalytic activity suggesting that it has a more complex role in the regulation of JAK2 activity. Our study also shows that the domains located outside the kinase domain have little influence on JAK2 catalytical activity.
No takes yet. Share an insight, caveat, or question.
Erdmann et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: